The first drug is blinatumomab (Blincyto®) which can bind to CD3 on T cells and to CD19 on B cells and is used in the treatment of Philadelphia chromosome-negative (Ph-) relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL) [205,206]. This evidence concerns the gene CD19 and acute lymphoblastic leukemia.